期刊文献+

接种Aβ_(42)全肽疫苗恒河猴的特异性体液免疫应答 被引量:6

Specific humoral immuneresponse in Rhesus monkeys vaccinated immune response with Aβ_(42) peptide vaccine
下载PDF
导出
摘要  目的: 观察恒河猴接种Aβ42肽疫苗后的特异性抗体的产生。方法: 将 5只雄性恒河猴分别在 0、2、6、10、14、18、22wk肌内注射Aβ42肽疫苗; 用ELISA法检测恒河猴血清抗Aβ42抗体水平及IgG亚类; 用Westernblot检测血清抗Aβ42抗体的特异性; 免疫组化染色法观察抗血清对Tg2576转基因小鼠脑组织中Aβ斑的识别。结果: 疫苗接种后第 8周, 恒河猴血清中出现明显的抗Aβ42抗体, 抗体水平随着接种次数的增加而升高, 第 24周达 1∶4 320, 以后抗体水平开始下降。产生的抗Aβ42抗体以IgG1和IgG2为主 (IgG2 /IgG1 >1)。血清抗Aβ42抗体具有高度特异性, 可识别Tg2576转基因小鼠脑组织中的Aβ斑。结论: Aβ42肽疫苗可有效地诱导恒河猴产生特异性体液免疫应答。 AIM: To observe the humoral immuneresponse in Rhesus monkey induced by Aβ 42 peptide vaccination. METHODS: Five male Rhesus monkeys received intramuscular injection of Aβ 42 peptide vaccine at 0, 2nd, 6th, 10th, 14th, 18th, 22th week. The titers and Ig subclasses of the serum anti-Aβ 42 antibody were measured by ELISA. The specificity of the anti-Aβ 42 antibody was determined by Western blot. The recognition of Aβ plaques in Tg2576-transgenic mouse brain tissue by anti-Aβ 42 serum were detected by immunohistochemical staining. RESULTS: At the 8th week after the vaccination, the serum anti-Aβ 42 antibody was detected. The titers of the antibody increased with times of booster inoculation and reached 1∶4 320 at the 24th week, then decreased. The produced antibodies were mainly IgG1 and IgG2(IgG2/IgG1>1). The anti-Aβ 42 antibody had high specificity. The Aβ plaques in Tg2576-transgenic mouse brain tissue were recognized by the antisera. CONCLUSION: Aβ 42 peptide vaccine can induce effectively specific humoral immuneresponse in Rhesus monkey.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2005年第2期202-204,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目 (No. 30400512 ) 广东省自然科学基金重大项目 (No. 20013137 ) 广东省自然科学基金(No. 04300218) 中山市科技局重点攻关项目(No. 4209606)
关键词 阿尔茨海默病 Β淀粉样肽 疫苗 体液免疫应答 恒河猴 Alzheimer’s disease β amyloid peptide vaccine humoral immune response Rhesus monkey
  • 相关文献

参考文献10

  • 1胡金家,汪华侨,曲怀刚,徐杰,姚志彬.Aβ_(42)及亚单位疫苗诱导小鼠抗体产生及其中和Aβ_(42)的细胞毒性[J].细胞与分子免疫学杂志,2004,20(2):178-181. 被引量:29
  • 2Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999, 400(6740): 173-177.
  • 3Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer' s disease[J]. Nature, 2000, 408(6815): 979-982.
  • 4Check E. Nerve inflammation halts trial for Alzheimer' s drug[J]. Nature, 2002, 415(6871): 462.
  • 5Frenkel D, Katz O, Solomon B. Immunization against Alzheimer' s beta-amyloid plaques via EFRH phage administration[J]. Proc Natl Acad Sci USA, 2000, 97(21): 11455-11459.
  • 6Monsonego A, Maron R, Zota V, et al. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer' s disease[J]. Proc Natl Acad Sci USA, 2001, 98(18): 10273-10278.
  • 7李国营,张革,胡金家,汪华侨,邱国光,姚志彬.APPSWE转基因鼠的繁育及子代鉴定的研究[J].中国病理生理杂志,2004,20(1):113-116. 被引量:18
  • 8Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease[J]. Exp Neurol, 2004, 188(1): 52-64.
  • 9Sani S, Traul D, Klink A, et al. Distribution, progression and chemical composition of cortical amyloid-βdeposits in aged rhesus monkey: similarities to the human[J]. Acta Neuropathol, 2003, 105(2): 145-156.
  • 10Dickey CA, Morgan DG, Kudchodkar S, et al. Duration and specificity of humoral immune responses in Mice vaccinated with the Alzheimer' s disease-associated β-amyloid 1- 42 peptide[J]. DNA Cell Biology, 2001, 20(11): 723-729.

二级参考文献12

  • 1Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999, 400(6740): 173 - 177.
  • 2Arendash GW, Gordon MN, Diamond DM, et al. Behavioral assessment of Alzheimer' s transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition andspatial memory [ J]. DNA Cell Biol, 2001, (11): 737 -744.
  • 3Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the endof the beginning [J]. Nat Rev Neurosci, 2002, 3(10): 824 -828.
  • 4Ott G. The adjuvant MF59: the 1998 perspective, clinical, persormanceand mechanism of action [J]. Res immunol, 1998, 149:25 -27.
  • 5J Mclaurin R, Cecal ME, Kierstead, et al. Therapeutically effectiveantibodies against amyliod-β residues 4-10 and inhibit cytotoxity andfibrillogenesis [ J ]. Nat Med, 2002, 8 ( 11 ): 1263 - 1269.
  • 6Ott G, Barchfeld GL, Van Nest G, et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59 [J]. Vaccine, 1995, 13(16): 1557-1562.
  • 7Plduslo JF, Cunan GL. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brainbarrier [J]. Neuroreport, 2001, 12(15): 3197-3200.
  • 8Dohart JC, Bales Kr, Gannon KS, et al. Immunizarion reverses memory deficits without reducing brain Aβ burden in Alzheimer' s diseasemodel [J]. Nat Neurosci, 2002, 5 (5): 452 -457.
  • 9Jams AR, Nicoll, David W, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report[J]. NatMed, 2003, 10: 1-5.
  • 10常洋,秦川,尹红星,朱华,蔡有余.建立阿尔茨海默症的转基因动物模型[J].解剖学报,2000,31(2):144-147. 被引量:38

共引文献41

同被引文献74

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部